circle

INVESTORS & MEDIA

INVESTOR OVERVIEW

  • Webcast
    X Raymond James Human Health Innovation Conference
    Jun 21, 2021 2:00 PM EDT

    Raymond James Human Health Innovation Conference
    Jun 21, 2021 2:00 PM EDT
  • Webcast
    X JMP Securities Life Sciences Conference
    Jun 16, 2021 4:00 PM EDT

    JMP Securities Life Sciences Conference
    Jun 16, 2021 4:00 PM EDT
  • Webcast
    X Goldman Sachs 42nd Annual Global Healthcare Conference
    Jun 9, 2021 3:00 PM EDT

    Goldman Sachs 42nd Annual Global Healthcare Conference
    Jun 9, 2021 3:00 PM EDT

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. More >>

ANNUAL REPORT

CORPORATE PRESENTATION

CYTOKINETICS FACT SHEETS

fact1

Company

09/21/18
( FY )
ALS

ALS

03/11/18
( FY )
SMA

SMA

07/13/18
( FY )

NEWS

Date Title and Summary
Toggle Summary Cytokinetics Announces Completion of Enrollment in METEORIC-HF, The Second Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure With Reduced Ejection Fraction
Top Line Results of METEORIC-HF Expected in Early 2022 Company Plans to Submit NDA in 2H 2021 Based on Positive Results of GALACTIC-HF SOUTH SAN FRANCISCO, Calif. , June 15, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the completion of patient enrollment in
Toggle Summary Cytokinetics to Participate in Upcoming Investor Conferences
SOUTH SAN FRANCISCO, Calif. , June 02, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to participate in three virtual fireside chats at the following investor conferences: 42 nd Annual
Toggle Summary Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif. , June 01, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on May 31, 2021 it granted stock options to purchase an aggregate of 49,500 shares of common stock to eight new employees whose employment commenced in May 2021 as a
Toggle Summary Cytokinetics and The ALS Association Renew Partnership to Advance the Fight Against ALS
SOUTH SAN FRANCISCO, Calif. and WASHINGTON , May 19, 2021 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) and The ALS Association today announced the continuation of their partnership in the fight against ALS. Cytokinetics is a sponsor of the 2021 ALS Roundtables and ALS Focus, a

EVENTS

There are currently no events to display.